Canine CCL8 (C–C motif chemokine ligand 8, also known as MCP-2 – Monocyte Chemoattractant Protein-2) is a proinflammatory chemokine that regulates leukocyte recruitment and inflammatory responses in dogs (Canis lupus familiaris). CCL8 is a member of the CC chemokine family, which includes related chemokines such as CCL2 (MCP-1), CCL7 (MCP-3), and CCL13 (MCP-4) that coordinate monocyte and leukocyte trafficking during immune activation. In dogs, CCL8 is produced by macrophages, fibroblasts, endothelial cells, epithelial cells, and other immune cells in response to infection, inflammatory cytokines, or tissue injury. CCL8 exerts its biological effects through interaction with chemokine receptors including CCR1, CCR2, CCR3, and CCR5, promoting chemotaxis and activation of monocytes, macrophages, dendritic cells, T lymphocytes, and eosinophils at sites of infection or inflammation. In canine health, CCL8 likely contributes to immune responses against viral and bacterial pathogens and participates in chronic inflammatory and immune-mediated diseases such as canine atopic dermatitis and inflammatory bowel disease, where chemokine-driven leukocyte recruitment plays a key role in disease pathology. Because dogs develop several naturally occurring diseases that resemble human inflammatory and allergic conditions, canine CCL8 is also studied in comparative animal models of inflammatory disease and immune regulation, helping to improve understanding of chemokine signaling pathways and leukocyte trafficking in both veterinary and human medicine.